Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
July 26 2021 - 3:18PM
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage
biopharmaceutical company focused on therapeutics for rare
diseases, announced that Mark Bach, M.D., Ph.D., accepted his
appointment to the Company’s Clinical Scientific Advisory Board
(CSAB) effective July 15, 2021. Dr. Bach joins the Company’s
accomplished advisory board comprised of noted pediatric
endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D.,
Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld,
M.D.
Dr. Bach is currently the Chief Medical Officer
for ShouTi Inc., having recently joined from Ascendis Pharma where
he served as Senior Vice President, Endocrine Medical Sciences. Dr.
Bach is a pediatric endocrinologist with 30 years of clinical
research and pharmaceutical development experience, including
extensive global experience building and leading clinical teams
that have successfully launched innovative pharmaceutical products
into worldwide markets. Prior to Ascendis, Dr. Bach spent nine
years at Janssen, a subsidiary of Johnson & Johnson, where he
held successive leadership roles in research and development,
culminating in the position of Head of Asia Pacific Medical
Sciences and Head of China R&D. Prior to Janssen, Dr. Bach held
positions of increasing responsibility in Clinical Research at
Merck & Co., Inc., ending his tenure there as Vice President of
Clinical Research Operations Worldwide. Early in his career, Dr.
Bach conducted extensive clinical and preclinical research on
growth hormone, IGF-1 and LUM-201 (MK-0677), with data from this
work published in scientific and medical journals.
“Dr. Mark Bach brings to our advisory board a
wealth of knowledge of, and experience with, growth hormone related
disorders and a significant understanding of the unique advantages
LUM-201 could offer to the growth hormone deficient population,”
said Rick Hawkins, CEO, President and Chairman of Lumos Pharma. “We
are thrilled to have Dr. Bach join the other esteemed members of
our CSAB and look forward to his contributions to Lumos Pharma’s
clinical and commercial strategy.”
“Children with growth hormone deficiency have
had to endure growth hormone injections as the only treatment
option for over thirty years,” said Mark Bach. “Lumos Pharma’s
novel oral therapeutic candidate, LUM-201 could provide a welcome
alternative for many of these children. Through my research at
Merck, I saw firsthand the promising clinical data supporting
LUM-201 and am excited to join fellow advisory board members to
assist Lumos Pharma in advancing this compound and executing on its
clinical strategy.”
Throughout his career, Dr. Bach has authored
numerous publications, has lectured in national and international
forums and has served on professional society advisory boards to
advance the field of endocrinology and clinical research. Dr. Bach
is an active member of The Endocrine Society and has served on
several of this organization’s committees. Dr. Bach received a B.A.
in chemistry from Carleton College where he was awarded Phi Beta
Kappa, received an M.D. from Baylor College of Medicine and a Ph.D.
in pathology from The University of Chicago. Dr. Bach completed his
pediatric residency at the Baylor College of Medicine and completed
a pediatric endocrinology fellowship and post-doctoral research at
the National Institute of Health, working in the laboratories of
Drs. Derek LeRoith and Carolyn Bondy.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos Pharma
was founded and is led by a management team with longstanding
experience in rare disease drug development and received early
funding from leading healthcare investors, including Deerfield
Management, a fund managed by Blackstone Life Sciences, Roche
Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and
UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral
growth hormone stimulating small molecule, currently being
evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and
a PK/PD trial, the OraGrowtH212 Trial, for the treatment of
Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA,
LUM-201 would provide an orally administered alternative to daily
injections that current PGHD patients endure for many years of
treatment. LUM-201 has received Orphan Drug Designation in both the
US and EU. For more information, please visit
https://lumos-pharma.com/.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements of Lumos Pharma, Inc. (the “Company”) that involve
substantial risks and uncertainties. All such statements contained
in this press release are forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words “forecast,” “projected,” "guidance," "upcoming," "will,"
“would,” "plan," “intend,” "anticipate," "approximate," "expect,"
“potential,” “imminent,” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include,
among others, the ability of prior research results to forecast the
performance of therapeutic agents in the clinic, anticipated
business development activities, anticipated market reception to
our treatment regimen for PGHD and other indications, plans related
to initiation and execution of clinical trials; plans related to
moving additional indications into clinical development; future
financial performance, results of operations, cash position and
sufficiency of capital resources to fund its operating
requirements; and any other statements other than statements of
historical fact. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the
forward-looking statements that the Company makes due to a number
of important factors, including the effects of pandemics or other
widespread health problems, the outcome of our future interactions
with regulatory authorities, our ability to project future cash
utilization and reserves needed for contingent future liabilities
and business operations, the ability to obtain the necessary
patient enrollment for our product candidate in a timely manner,
the ability to successfully develop our product candidate, the
timing and ability of Lumos to raise additional equity capital as
needed and other risks that could cause actual results to differ
materially from those matters expressed in or implied by such
forward-looking statements as discussed in "Risk Factors" and
elsewhere in Lumos Pharma’s Annual Report on Form 10-K for the year
ended December 31, 2020 and other reports filed with the SEC. The
forward-looking statements in this press release represent the
Company’s views as of the date of this press release. The Company
anticipates that subsequent events and developments will cause
their views to change. However, while it may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing the Company’s views as of any date subsequent to the
date of this press release.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From Apr 2024 to May 2024
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From May 2023 to May 2024